sugemalimab,Fluorouracil,Cisplatin
cstone pharmaceuticals,pfizer
['sugemalimab', 'ct041,st,01', 'ca,022,i', 'gi ', 'nous,pev', 'cisplatin', 'ca,022,1', 'gemstone-304', 'nct04187352', 'ct041', 'esophageal']
sugemalimab plus chemo vs placebo plus chemo in 1st line treatment of advanced esophageal carcinoma: pfs (hr 0.57), os (hr 0.79) and orr (60.1% vs 45.2%). in subgroup analysis benefit was restricted to ihc pd-l1 cps 10 #wcgic2023 
MD de la UN. Especialista en medicina interna, docencia y oncología.